Generic pharma powerhouse CORONA Remedies has reported a strong set of unaudited financial results for the second quarter and half year ended September 30, 2025, underscoring robust revenue momentum and sharp profit growth.

 

The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half, marking year-on-year growth of 15.1% and 17.0% respectively. Profit after tax climbed even faster, reaching Rs. 52.32 crore for the quarter and Rs. 98.52 crore for the half year, up 21.8% and 35.1% year-on-year.

 

Management attributed the performance to disciplined execution, a sharper focus on core therapies and continued outperformance versus the broader Indian pharmaceutical market.

 

Commenting on the results, Nirav K. Mehta, Managing Director and CEO, CORONA Remedies Limited, said: “We are delighted to report a strong financial performance in Q2 and H1 FY26. Revenues for Q2 and H1FY26 grew by 15.1% and 17.0% respectively on a Y-o-Y basis, outperforming the IPM growth. Profit after tax for Q2 and H1FY26 grew by 21.8% and 35.1% respectively on a Y-o-Y basis while maintaining healthy return ratios. 

 

"Our strong performance reflects the consistency of our strategy, disciplined execution and deep focus on our core therapeutic segments. By strengthening our field force, expanding our brand portfolio and maintaining a sharp focus on specialists prescriptions, we have continued to outperform the market while building a sustainable platform for long-term growth.

 

"Lastly, we are grateful to our bankers for their efforts in the successful listing of CORONA on the Indian stock exchanges. I would also like to thank the entire team at CORONA and our stakeholders for their continued support and faith in our business.”